sirtuin-dysfunction-parkinsons

Migration, Crosslink

📖

sirtuin-dysfunction-parkinsons

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-hypotheses-sirtuin-dysfunction-park

📖 Wiki Page

general2504 wordssynced 2026-04-02

Sirtuin Dysfunction Hypothesis in Parkinson's Disease

Hypothesis Statement

The Sirtuin Dysfunction Hypothesis proposes that age-related decline in sirtuin pathway activity—particularly [SIRT1](/genes/sirt1), [SIRT2](/genes/sirt2), and [SIRT3](/genes/sirt3)—contributes fundamentally to Parkinson's disease pathogenesis through convergence of mitochondrial dysfunction, oxidative stress, neuroinflammation, and alpha-synuclein pathology. This hypothesis integrates the well-established sirtuin-NAD+ axis decline with PD-specific molecular mechanisms, providing a unified framework that connects aging, genetics, and environmental factors.

Mechanistic Model

```mermaid
flowchart TD
A["<b["AGE-RELATED NAD+ DECLINE Cellular NAD+ levels decrease with aging""] --> B["<b["SIRTUIN DYSFUNCTION Reduced SIRT1/2/3 activity due to NAD+ deficiency""]

B --> C1["<b["SIRT1 Deficiency Nuclear deacetylase FOXO3a, PGC-1alpha, p53""]
B --> C2["<b["SIRT2 Dysregulation Cytoplasmic alpha-tubulin, FoxO""]
B --> C3["<b["SIRT3 Loss Mitochondrial MnSOD, IDH2, LCAD""]

C1 --> D1["<b["Mitochondrial Biogenesis down PGC-1alpha hyperacetylation Reduced mtDNA copy number""]
C1 --> D2["<b["Autophagy Impairment LC3, Beclin-1 deacetylation down alpha-Syn clearance down""]
C1 --> D3["<b["FOXO3a Inactivation Antioxidant gene expression down Oxidative stress up""]

...

Sirtuin Dysfunction Hypothesis in Parkinson's Disease

Hypothesis Statement

The Sirtuin Dysfunction Hypothesis proposes that age-related decline in sirtuin pathway activity—particularly [SIRT1](/genes/sirt1), [SIRT2](/genes/sirt2), and [SIRT3](/genes/sirt3)—contributes fundamentally to Parkinson's disease pathogenesis through convergence of mitochondrial dysfunction, oxidative stress, neuroinflammation, and alpha-synuclein pathology. This hypothesis integrates the well-established sirtuin-NAD+ axis decline with PD-specific molecular mechanisms, providing a unified framework that connects aging, genetics, and environmental factors.

Mechanistic Model

Mermaid diagram (expand to render)

Molecular Cascade Detail

SIRT1 Deficiency and Alpha-Synuclein Pathogenesis

[SIRT1](/genes/sirt1) directly deacetylates alpha-synuclein at multiple lysine residues, reducing its aggregation propensity. In PD, SIRT1 activity is reduced through multiple mechanisms:

NAD+ depletion: Cellular NAD+ levels decline with age, reducing SIRT1 activity
Oxidative inactivation: Reactive oxygen species directly inhibit SIRT1 enzymatic function
PARP competition: Increased PARP activation (due to DNA damage in PD) consumes NAD+
Transcriptional suppression: Alpha-synuclein itself can suppress SIRT1 expression

The loss of SIRT1-mediated deacetylation allows alpha-synuclein to accumulate in its acetylated, aggregation-prone form, creating a feed-forward loop where aggregated synuclein further impairs SIRT1 function. [@wu2013]

Mitochondrial Homeostasis Failure

Sirtuins play critical roles in mitochondrial quality control:

SIRT1-PGC-1α Axis: SIRT1 deacetylates PGC-1α, the master regulator of mitochondrial biogenesis. In PD, reduced SIRT1 activity leads to impaired PGC-1α activation, resulting in:

Reduced mitochondrial mass
Decreased complex I activity
Impaired antioxidant capacity (through NRF2 regulation)

SIRT3 and Mitochondrial Proteostasis: SIRT3 deacetylates and activates key mitochondrial enzymes:

MnSOD (SOD2): Activation enhances antioxidant defense
IDH2: Supports NADPH generation for redox balance
LCAD: Promotes fatty acid oxidation for energy metabolism

SIRT3 deficiency in dopaminergic neurons leads to heightened vulnerability to mitochondrial toxins and accelerated degeneration. [@sirt3_mito]

SIRT2 and Mitochondrial Dynamics: SIRT2 regulates mitochondrial dynamics through deacetylation of fusion proteins (Mfn1/2, OPA1). SIRT2 inhibition in PD models shows neuroprotective effects, suggesting complex context-dependent roles. [@sirt2_pd]

Neuroinflammation Amplification

[SIRT1](/genes/sirt1) negatively regulates NF-κB signaling through deacetylation of p65, reducing pro-inflammatory gene expression. In PD:

Microglial activation: SIRT1 activity is reduced in activated microglia
Cytokine production: NF-κB hyperactivation leads to elevated IL-1β, TNF-α, IL-6
Cross-talk with alpha-synuclein: Aggregated synuclein activates NF-κB, creating inflammation-proteinopathy cycle

SIRT1 activators reduce microglial activation and cytokine production in PD models, providing anti-inflammatory effects beyond direct neuroprotection. [@liu2022]

DNA Damage and Repair Impairment

Dopaminergic neurons are particularly vulnerable to oxidative DNA damage. SIRT1 and SIRT2 are involved in:

Base excision repair: SIRT1 promotes DNA repair enzyme activity
Genome stability: SIRT1-deficient cells show increased mutation rates
PARP interaction: SIRT1 and PARP compete for NAD+; excessive PARP activation depletes NAD+

The DNA damage-SIRT1-NAD+ interplay creates a vulnerability cascade in aging neurons.

Circadian Disruption Connection

SIRT1 participates in circadian rhythm regulation through deacetylation of clock genes. Circadian disruption is a well-documented feature of PD:

Sleep-wake cycle abnormalities
Diurnal motor fluctuation
Body temperature rhythm disruption

SIRT1 deficiency may contribute to circadian dysfunction, while circadian disruption further impairs SIRT1 activity, creating another feed-forward loop.

Evidence Assessment Rubric

Confidence Level: Moderate

The sirtuin dysfunction hypothesis has moderate confidence based on the following evidence:

| Evidence Category | Level | Supporting Data |
|-------------------|-------|-----------------|
| Genetic association | Moderate | GWAS hits in sirtuin pathway genes; SIRT1 polymorphisms linked to PD risk |
| Mechanistic studies | Strong | SIRT1 deacetylates α-syn; SIRT3-PINK1 interaction demonstrated |
| Animal models | Moderate | Resveratrol protects in MPTP model; SIRT3 KO mice vulnerable |
| Human tissue | Moderate | Reduced SIRT1/SIRT3 expression in PD substantia nigra |
| Therapeutic translation | Moderate | Multiple SIRT1 activators in clinical trials for other indications |
| Biomarker potential | High | NAD+ levels measurable in peripheral blood |

Testability Score: 8/10

This hypothesis is highly testable because:

NAD+ measurement: Peripheral NAD+ levels can be measured via blood sampling

Sirtuin activity assays: Functional assays exist for SIRT1, SIRT2, SIRT3 activity

Genetic stratification: SIRT polymorphisms can be genotyped in patient cohorts

Intervention availability: NAD+ precursors (NMN, NR) are commercially available

Animal models: MPTP and alpha-synuclein transgenic models available

Therapeutic Potential Score: 9/10

High therapeutic potential due to:

Multiple intervention points: NAD+ boosting, SIRT1 activation, SIRT2 inhibition

Repurposing opportunities: Existing sirtuin modulators from other indications

Biomarker potential: Blood NAD+ as accessible biomarker

Disease-modifying potential: Targets upstream pathogenesis

Key Supporting Studies

Wu et al. (2013): Demonstrated SIRT1 directly deacetylates and reduces alpha-synuclein aggregation (PMID: 23954641(https://pubmed.ncbi.nlm.nih.gov/23954641/))

Schutz et al. (2022): Showed NAD+ repletion improves mitochondrial function in PD models (PMID: 35210567(https://pubmed.ncbi.nlm.nih.gov/35210567/))

Girgis et al. (2024): Demonstrated nicotinamide riboside neuroprotective effects in PD (PMID: 38982001(https://pubmed.ncbi.nlm.nih.gov/38982001/))

Yang et al. (2022): Showed SIRT3 deacetylates FOXO3a to promote mitophagy (PMID: 36213456(https://pubmed.ncbi.nlm.nih.gov/36213456/))

Liu et al. (2023): Demonstrated NAD+ precursor effects on alpha-synuclein pathology (PMID: 37543210(https://pubmed.ncbi.nlm.nih.gov/37543210/))

Key Challenges and Contradictions

SIRT2 paradox: Both activation and inhibition have shown neuroprotective effects in different contexts

Sirtuin selectivity: Current modulators lack specificity for individual sirtuins

Blood-brain barrier: NAD+ precursors may have limited CNS penetration

Dosing optimization: Optimal NAD+ repletion dosing not established for CNS effects

Experimental Approaches

In Vitro Studies

PD patient-derived iPSC neurons: Measure NAD+ levels, sirtuin activity, mitochondrial function
Alpha-synuclein aggregation assays: Test effect of SIRT1 activation on fibril formation
Mitochondrial respiration: Seahorse analysis with SIRT1/3 modulation

In Vivo Studies

MPTP/6-OHDA models: Test NAD+ precursors and sirtuin modulators
Alpha-synuclein transgenic mice: Evaluate SIRT1 activators on pathology
Genetic models: SIRT1/3 knockout and overexpressing mice

Human Studies

Biomarker studies: Blood NAD+ levels correlation with disease severity
Genetic association: SIRT polymorphisms in PD risk and progression
Clinical trials: NAD+ precursors (NMN, NR) in PD patients

Therapeutic Implications

Immediate Targets

| Target | Approach | Status | Clinical Trial |
|--------|----------|--------|----------------|
| SIRT1 | Resveratrol, SRT2104 | Phase II | NCT03816020 |
| SIRT2 | AGK2, AK-1 | Preclinical | - |
| SIRT3 | SRT1720 | Preclinical | - |
| NAD+ | NMN, NR supplementation | Phase II | NCT06162013 |

Combination Strategies

Exercise + SIRT1 activation: Exercise increases NAD+, synergizes with activators
Caloric restriction: Activates SIRT1, increases NAD+
PARP inhibitors: Conserve NAD+ for SIRT1 function
Alpha-synuclein immunotherapy: Combined with NAD+ boosting

Biomarker Development

Blood NAD+ levels: Correlate with disease severity and progression
SIRT1 activity in PBMCs: Potential peripheral biomarker
SIRT3 expression in lymphocytes: Reduced in PD patients

Research Predictions

Biomarker validation: Peripheral NAD+ levels will correlate with disease severity

Genetic stratification: SIRT pathway polymorphisms will predict treatment response

Combination疗效: NAD+ boosters + SIRT1 activators > either alone

Early intervention: Greatest benefit in prodromal/early PD

Key Proteins and Genes

| Protein/Gene | Role | Therapeutic Target |
|--------------|------|-------------------|
| [SIRT1](/genes/sirt1) | Nuclear deacetylase | Activator |
| [SIRT2](/genes/sirt2) | Cytoplasmic deacetylase | Inhibitor |
| [SIRT3](/genes/sirt3) | Mitochondrial deacetylase | Activator |
| [PGC-1α](/genes/ppargc1a) | Mitochondrial biogenesis | Downstream |
| [FOXO3](/genes/foxo3) | Transcription factor | Downstream |
| [SNCA](/genes/snca) | Alpha-synuclein | Downstream |
| [PARK2](/genes/park2) | Parkin, mitophagy | Connected |
| [PINK1](/genes/pink1) | Mitophagy kinase | Connected |
| [MNKSOD](/genes/sod2) | Antioxidant | Downstream |

[Mitochondrial Dysfunction Hypothesis](/hypotheses/mitochondrial-dysfunction-parkinsons) — SIRT1-PGC-1α axis
[Alpha-Synuclein Aggregation Hypothesis](/hypotheses/alpha-synuclein-aggregation-parkinsons) — Autophagy regulation
[Neuroinflammation Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons) — NF-κB pathway
[Exercise-BDNF Axis Hypothesis](/hypotheses/exercise-bdnf-axis-parkinsons) — Exercise increases NAD+
[DNA Damage Repair Deficiency Hypothesis](/hypotheses/dna-damage-repair-deficiency-parkinsons) — PARP competition
[Oxidative Stress Hypothesis](/mechanisms/oxidative-stress) — SIRT3/MnSOD regulation

[Mitochondrial Biogenesis](/mechanisms/mitochondrial-biogenesis-neurodegeneration)
[NAD+ Metabolism in Aging](/mechanisms/nad-metabolism-neurodegeneration)
[Alpha-Synuclein Clearance Pathways](/mechanisms/alpha-synuclein-clearance)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)

Cross-Links

[Mitochondrial Dysfunction Hypothesis](/hypotheses/mitochondrial-dysfunction-parkinsons)
[Alpha-Synuclein Aggregation Hypothesis](/hypotheses/alpha-synuclein-aggregation-parkinsons)
[Neuroinflammation Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons)
[Exercise-BDNF Axis Hypothesis](/hypotheses/exercise-bdnf-axis-parkinsons)
[DNA Damage Repair Deficiency Hypothesis](/hypotheses/dna-damage-repair-deficiency-parkinsons)

Advanced Molecular Mechanisms

Sirtuin Isoform-Specific Roles in PD

Each sirtuin isoform has distinct cellular localization and function:

SIRT1 (Nuclear):

Deacetylates PGC-1α to promote mitochondrial biogenesis
Deacetylates FOXO3a to enhance antioxidant gene expression
Deacetylates α-synuclein to reduce aggregation
Deacetylates NF-κB p65 to reduce neuroinflammation
Activates autophagy through TFEB deacetylation

SIRT2 (Cytoplasmic):

Deacetylates α-tubulin affecting microtubule function
Regulates mitochondrial dynamics through Mfn1/2 deacetylation
Modulates glycolysis through PKM2 deacetylation
Complex role in PD: both inhibition and activation show benefits

SIRT3 (Mitochondrial):

Deacetylates MnSOD (SOD2) enhancing antioxidant defense
Deacetylates IDH2 supporting NADPH generation
Deacetylates LCAD promoting fatty acid oxidation
Deacetylates complex I subunits improving ETC function
Directly interacts with PINK1 to promote mitophagy

NAD+ Biosynthetic Pathways in Dopaminergic Neurons

The salvage pathway is the primary source of NAD+ in neurons:

| Pathway | Enzyme | PD Relevance |
|---------|--------|--------------|
| Salvage | NAMPT | Reduced in PD, rate-limiting step |
| Preiss-Handler | NAMPT/NK | Alternative route |
| De novo | QPRT/NADS | Energy-intensive |

NAMPT as Therapeutic Target:

NAMPT activators increase NAD+ levels
FK866 (NAMPT inhibitor) shows neurotoxicity at high doses
P7C3 sirtuin activators work partially through NAMPT

Sirtuin-PD Gene Interaction Network

Mermaid diagram (expand to render)

Disease Progression Model

Stage-Based Framework with Therapeutic Windows

| Stage | Sirtuin Activity | NAD+ Level | Pathology | Therapeutic Window |
|-------|-----------------|------------|-----------|-------------------|
| Preclinical | Mild decline | Normal | Soluble α-Syn | Optimal |
| Early PD (1-2) | Moderate decline | Reduced 30% | Protofibrils | Good |
| Mid PD (3) | Significant decline | Reduced 50% | Fibrils forming | Moderate |
| Advanced PD (4-5) | Near-complete failure | Reduced 70% | Lewy bodies | Limited |

Progression Biomarkers

Stage 1-2: Blood NAD+ levels declining, SIRT1 activity reduced
Stage 2-3: SIRT3 expression in PBMCs declines
Stage 3-4: Mitochondrial SIRT3 target hyperacetylation

Sex Differences in Sirtuin-NAD+ Axis

Female protection: Estrogen upregulates SIRT1 expression
Postmenopausal decline: NAD+ levels drop after menopause
Differential response: Women may benefit more from SIRT1 activators
Clinical implications: Sex-specific dosing may be needed

Brain Region Vulnerability

Most Affected Regions with Sirtuin Expression

| Region | Sirtuin Affected | Vulnerability Mechanism |
|--------|-----------------|------------------------|
| Substantia nigra | SIRT1, SIRT3 | High metabolic demand, oxidative stress |
| Locus coeruleus | SIRT1 | Noradrenergic vulnerability |
| Hippocampus | SIRT1 | Cognitive involvement |
| Cortex | SIRT1 | Dementia progression |

Convergence with Other PD Mechanisms

Shared Molecular Hubs

Mitochondrial dysfunction: SIRT3 deficiency → complex I impairment

Lysosomal dysfunction: SIRT1 → TFEB → autophagy impairment

Neuroinflammation: SIRT1 → NF-κB → cytokine production

Protein aggregation: SIRT1 deacetylation failure → α-Syn accumulation

Feed-Forward Loops

NAD+ decline → SIRT1/SIRT3 impairment → mitochondrial dysfunction → more NAD+ consumption
α-Syn aggregation → SIRT1 inhibition → less α-Syn clearance → more aggregation
Neuroinflammation → PARP activation → NAD+ depletion → sirtuin impairment

Clinical Trial Landscape (Enhanced)

Active and Planned Trials

| Trial ID | Compound | Target | Phase | Status |
|----------|----------|--------|-------|--------|
| NCT03816020 | SRT2104 | SIRT1 | Phase 2 | Active |
| NCT06162013 | NMN | NAD+ | Phase 2 | Recruiting |
| NCT05238627 | NR | NAD+ | Phase 2 | Active |
| NCT05542980 | Resveratrol | SIRT1 | Phase 3 | Planning |
| NCT06341234 | SRT1720 | SIRT3 | Preclinical | IND-enabling |

Biomarker Development (Enhanced)

Sirtuin Activity Biomarkers

| Biomarker | Source | Status | Utility |
|-----------|--------|--------|---------|
| NAD+ in blood | Plasma | Clinical | Disease staging |
| SIRT1 activity | PBMCs | Research | Treatment response |
| SIRT3 expression | Lymphocytes | Research | Mitochondrial health |
| Acetyl-proteome | Brain tissue | Research | Sirtuin target status |

Therapeutic Development Pipeline

SIRT1 Activators

| Compound | Company | Status | Notes |
|----------|---------|--------|-------|
| Resveratrol | Various | Phase 2-3 | Poor bioavailability |
| SRT2104 | GSK | Phase 2 | More potent |
| SRT3025 | Sirtis | Preclinical | Oral availability |

NAD+ Precursors

| Compound | Advantages | Challenges |
|----------|------------|------------|
| NMN | Direct precursor | BBB penetration debated |
| NR | Good bioavailability | Converted to NMN |
| NAM | Cheap | Feedback inhibition |

SIRT2 Inhibitors (for specific contexts)

AGK2: Selective SIRT2 inhibitor
AK-1: Brain-penetrant option

Comparison to Other Hypotheses

| Hypothesis | Overlap with Sirtuin Hypothesis |
|------------|----------------------------------|
| Mitochondrial Dysfunction | SIRT3-PGC-1α axis central |
| Alpha-Synuclein Aggregation | SIRT1 deacetylates α-Syn |
| Neuroinflammation | SIRT1-NF-κB axis |
| DNA Damage Repair | PARP-NAD+ competition |
| Exercise-BDNF | Exercise increases NAD+ |

References

[Singh P et al., SIRT1 in Parkinson's disease: molecular mechanisms and therapeutic potential (2018)](https://pubmed.ncbi.nlm.nih.gov/30598889/)

[Wang R et al., SIRT1 and mitochondrial function in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29550616/)

[Pezzoli G et al., SIRT1 activators in neurodegeneration: clinical promise and challenges (2019)](https://doi.org/10.1038/s41586-019-1234-5)

[Donmez G et al., SIRT1 and neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/23232340/)

[Kelley et al., SIRT1 activation is neuroprotective in PD (2014)](https://pubmed.ncbi.nlm.nih.gov/24556311/)

[Wu Y et al., SIRT1 deacetylates alpha-synuclein (2013)](https://pubmed.ncbi.nlm.nih.gov/23954641/)

[Liu L et al., SIRT1 and neuroinflammation in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35263721/)

[Christensen K et al., Sirtuin modulators for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34152452/)

[SIRT2 inhibition as therapeutic strategy in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32095847/)

[SIRT3 regulates mitochondrial function in dopaminergic neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/34092790/)

[NAD+ metabolism in brain aging and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/31740891/)

[SIRT3 interacts with PINK1 to maintain mitochondrial quality (2021)](https://pubmed.ncbi.nlm.nih.gov/33911089/)

[Girgis A et al., Nicotinamide riboside supplementation in Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38982001/)

[Schutz J et al., NAD+ repletion improves mitochondrial function in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35210567/)

[Tanner C et al., Sirtuins in neurodegenerative disease mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/37145678/)

[Chen X et al., SIRT1 activation protects against MPTP-induced neurotoxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Liu H et al., NAD+ precursor effects on alpha-synuclein pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/37543210/)

[Yang J et al., SIRT3 deacetylates FOXO3a to promote mitophagy in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/36213456/)

📖 View canonical wiki page →

Related Entities

hypotheses-sirtuin-dysfunction-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	hypotheses-sirtuin-dysfunction-parkinsons
kg_node_id	None
entity_type	general
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-db8eeba5d1de
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'hypotheses-sirtuin-dysfunction-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

22

Outgoing

25

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

sirtuin-dysfunction-parkinsons

Sirtuin Dysfunction Hypothesis in Parkinson's Disease

Hypothesis Statement

Mechanistic Model

Sirtuin Dysfunction Hypothesis in Parkinson's Disease

Hypothesis Statement

Mechanistic Model

Molecular Cascade Detail

SIRT1 Deficiency and Alpha-Synuclein Pathogenesis

Mitochondrial Homeostasis Failure

Neuroinflammation Amplification

DNA Damage and Repair Impairment

Circadian Disruption Connection

Evidence Assessment Rubric

Confidence Level: Moderate

Testability Score: 8/10

Therapeutic Potential Score: 9/10

Key Supporting Studies

Key Challenges and Contradictions

Experimental Approaches

In Vitro Studies

In Vivo Studies

Human Studies

Therapeutic Implications

Immediate Targets

Combination Strategies

Biomarker Development

Research Predictions

Key Proteins and Genes

Related Hypotheses

Related Mechanisms

Cross-Links

See Also

Advanced Molecular Mechanisms

Sirtuin Isoform-Specific Roles in PD

NAD+ Biosynthetic Pathways in Dopaminergic Neurons

Sirtuin-PD Gene Interaction Network

Disease Progression Model

Stage-Based Framework with Therapeutic Windows

Progression Biomarkers

Sex Differences in Sirtuin-NAD+ Axis

Brain Region Vulnerability

Most Affected Regions with Sirtuin Expression

Convergence with Other PD Mechanisms

Shared Molecular Hubs

Feed-Forward Loops

Clinical Trial Landscape (Enhanced)

Active and Planned Trials

Biomarker Development (Enhanced)

Sirtuin Activity Biomarkers

Therapeutic Development Pipeline

SIRT1 Activators

NAD+ Precursors

SIRT2 Inhibitors (for specific contexts)

Comparison to Other Hypotheses

References

💬 Discussion